The Cost-Effectiveness of Initial Treatment of Multiple Myeloma in the U.S. With Bortezomib Plus Melphalan and Prednisone Versus Thalidomide Plus Melphalan and Prednisone or Lenalidomide Plus Melphalan and Prednisone With Continuous Lenalidomide Maintenance Treatment

The outlook for transplant-ineligible multiple myeloma patients has improved enormously over recent years with the incorporation of new agents into standard regimens. Novel regimens combine melphalan and prednisone (MP) with bortezomib (VMP), with thalidomide (MPT), and with lenalidomide with (MPR-R...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Garrison, Louis P., Wang, Si-Tien, Huang, Hui, Ba-Mancini, Abbie, Shi, Hongliang, Chen, Kristina, Korves, Caroline, Dhawan, Ravinder, Cakana, Andrew, van de Velde, Helgi, Corzo, Deyanira, Duh, Mei Sheng
Format: Artigo
Langue:Inglês
Publié: AlphaMed Press 2013
Sujets:
Economics of Oncology Practice
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3556252/
https://ncbi.nlm.nih.gov/pubmed/23299777
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0380
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires